BRPI0606774A2 - método para o tratamento de um paciente humano que tem carcinoma de célula renal e uso de il-2 - Google Patents
método para o tratamento de um paciente humano que tem carcinoma de célula renal e uso de il-2Info
- Publication number
- BRPI0606774A2 BRPI0606774A2 BRPI0606774-3A BRPI0606774A BRPI0606774A2 BR PI0606774 A2 BRPI0606774 A2 BR PI0606774A2 BR PI0606774 A BRPI0606774 A BR PI0606774A BR PI0606774 A2 BRPI0606774 A2 BR PI0606774A2
- Authority
- BR
- Brazil
- Prior art keywords
- cell carcinoma
- renal cell
- treating
- human patient
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
MéTODO PARA O TRATAMENTO DE UM PACIENTE HUMANO QUE TEM CARCINOMA DE CéLULA RENAL E USO DE IL-2. São revelados métodos para o tratamento de carcinoma de célula renal que usam baixas doses de IL-2. Em particular, a invenção relaciona-se a métodos de tratamento de carcinoma de célula renal metastático em pacientes que têm insuficiência renal e/ou intolerantes à terapia com alta dose de IL-2. O regime terapêutico aqui descrito inibe de forma significativa o crescimento do tumor com toxicidade e efeitos colaterais adversos reduzidos comparado à terapia com alta dose de IL-2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64749605P | 2005-01-27 | 2005-01-27 | |
PCT/US2006/003116 WO2006081510A2 (en) | 2005-01-27 | 2006-01-27 | Methods for treating renal cell carcinoma |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0606774A2 true BRPI0606774A2 (pt) | 2009-07-14 |
Family
ID=36741121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0606774-3A BRPI0606774A2 (pt) | 2005-01-27 | 2006-01-27 | método para o tratamento de um paciente humano que tem carcinoma de célula renal e uso de il-2 |
Country Status (13)
Country | Link |
---|---|
US (2) | US20070014765A1 (pt) |
EP (1) | EP1846020B1 (pt) |
JP (2) | JP2008528621A (pt) |
KR (1) | KR20070102576A (pt) |
CN (1) | CN101132809A (pt) |
AU (1) | AU2006207987B2 (pt) |
BR (1) | BRPI0606774A2 (pt) |
CA (1) | CA2595959A1 (pt) |
ES (1) | ES2432141T3 (pt) |
IL (1) | IL184865A (pt) |
MX (1) | MX2007009012A (pt) |
RU (1) | RU2404795C2 (pt) |
WO (1) | WO2006081510A2 (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2370399A4 (en) * | 2008-12-11 | 2013-05-22 | Agency Science Tech & Res | GLUCOSE-PEG CONJUGATES TO REDUCE TRANSPORT OF GLUCOSE IN A CELL |
US20150299255A1 (en) * | 2010-11-01 | 2015-10-22 | Susavion Biosciences, Inc. | Compositions and methods for modulating innate and adaptive immune systems |
CA2860170C (en) | 2010-12-22 | 2022-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
BR112013023151A2 (pt) * | 2011-03-11 | 2020-09-15 | Assistance Publique - Hôpitaux De Paris | interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado |
CA2925421C (en) | 2013-09-24 | 2023-08-29 | Medicenna Therapeutics, Inc. | Interleukin-2 fusion proteins and uses thereof |
JP6592505B2 (ja) | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
CN113234138A (zh) | 2014-08-11 | 2021-08-10 | 德里尼亚公司 | 选择性地活化调节性t细胞用于治疗自身免疫病的修饰的il-2变体 |
US10350260B2 (en) * | 2015-04-27 | 2019-07-16 | Susavion Biosciences, Inc. | Compositions and methods for treating cancer and persistent viral infections |
WO2016175878A1 (en) * | 2015-04-27 | 2016-11-03 | Susavion Biosciences, Inc. | Compositions and methods for treating cancer and persistent viral infections |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
AU2017359172A1 (en) | 2016-11-08 | 2019-05-16 | Delinia, Inc. | IL-2 variants for the treatment of autoimmune diseases |
CU24483B1 (es) * | 2016-11-15 | 2020-04-02 | Ct Inmunologia Molecular | Método para incrementar los niveles de secreción de la interleucina-2 |
BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
WO2018215936A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
JP7433051B2 (ja) | 2017-06-19 | 2024-02-19 | メディシナ セラピューティクス インコーポレイテッド | Il-2スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法 |
TWI821192B (zh) | 2017-07-11 | 2023-11-11 | 美商新索思股份有限公司 | 非天然核苷酸之導入及其方法 |
BR112020002271A2 (pt) | 2017-08-03 | 2020-07-28 | Synthorx, Inc. | conjugados de citocina para o tratamento de doenças proliferativas e infecciosas |
CN111615396A (zh) * | 2017-11-21 | 2020-09-01 | 小利兰·斯坦福大学董事会 | 白介素-2的部分激动剂 |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
CN114949240A (zh) | 2019-02-06 | 2022-08-30 | 新索思股份有限公司 | Il-2缀合物及其使用方法 |
TW202110885A (zh) | 2019-05-20 | 2021-03-16 | 美商潘迪恩治療公司 | 靶向MAdCAM之免疫耐受性 |
BR112022012112A2 (pt) | 2019-12-20 | 2022-09-06 | Regeneron Pharma | Agonistas de il2 e métodos de uso dos mesmos |
JP2023514010A (ja) | 2020-01-10 | 2023-04-05 | ブライト ピーク セラピューティクス エージー | 修飾il-2ポリペプチドおよびその使用 |
EP4107187A4 (en) | 2020-02-21 | 2024-07-03 | Pandion Operations Inc | TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4752585A (en) * | 1985-12-17 | 1988-06-21 | Cetus Corporation | Oxidation-resistant muteins |
US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4931543A (en) * | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
US5830452A (en) * | 1990-11-20 | 1998-11-03 | Chiron Corporation | Method for enhancing the anti-tumor therapeutic index of interleukin-2 |
AU2003280442B2 (en) * | 2002-07-01 | 2009-02-05 | Wilex Ag | Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas |
-
2006
- 2006-01-27 KR KR1020077019556A patent/KR20070102576A/ko not_active Application Discontinuation
- 2006-01-27 MX MX2007009012A patent/MX2007009012A/es active IP Right Grant
- 2006-01-27 CN CNA2006800067217A patent/CN101132809A/zh active Pending
- 2006-01-27 WO PCT/US2006/003116 patent/WO2006081510A2/en active Application Filing
- 2006-01-27 AU AU2006207987A patent/AU2006207987B2/en not_active Ceased
- 2006-01-27 RU RU2007132125/14A patent/RU2404795C2/ru not_active IP Right Cessation
- 2006-01-27 US US11/342,243 patent/US20070014765A1/en not_active Abandoned
- 2006-01-27 BR BRPI0606774-3A patent/BRPI0606774A2/pt not_active Application Discontinuation
- 2006-01-27 JP JP2007553304A patent/JP2008528621A/ja active Pending
- 2006-01-27 ES ES06719806T patent/ES2432141T3/es active Active
- 2006-01-27 CA CA002595959A patent/CA2595959A1/en not_active Abandoned
- 2006-01-27 EP EP06719806.9A patent/EP1846020B1/en not_active Not-in-force
-
2007
- 2007-07-26 IL IL184865A patent/IL184865A/en active IP Right Grant
-
2009
- 2009-07-28 US US12/460,991 patent/US8012465B2/en not_active Expired - Fee Related
-
2011
- 2011-12-06 JP JP2011266809A patent/JP2012046552A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL184865A (en) | 2011-04-28 |
MX2007009012A (es) | 2007-09-14 |
KR20070102576A (ko) | 2007-10-18 |
WO2006081510A3 (en) | 2007-01-18 |
JP2008528621A (ja) | 2008-07-31 |
US20100316595A1 (en) | 2010-12-16 |
IL184865A0 (en) | 2007-12-03 |
JP2012046552A (ja) | 2012-03-08 |
EP1846020A2 (en) | 2007-10-24 |
WO2006081510A2 (en) | 2006-08-03 |
RU2007132125A (ru) | 2009-03-10 |
CN101132809A (zh) | 2008-02-27 |
ES2432141T3 (es) | 2013-11-29 |
US20070014765A1 (en) | 2007-01-18 |
US8012465B2 (en) | 2011-09-06 |
CA2595959A1 (en) | 2006-08-03 |
AU2006207987B2 (en) | 2011-09-15 |
EP1846020B1 (en) | 2013-08-21 |
AU2006207987A1 (en) | 2006-08-03 |
RU2404795C2 (ru) | 2010-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0606774A2 (pt) | método para o tratamento de um paciente humano que tem carcinoma de célula renal e uso de il-2 | |
Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration | Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials | |
BRPI0409919A (pt) | combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese | |
NO20061325L (no) | Kombinasjon av legemidler for behandling av neoplasmer | |
BRPI0406667A (pt) | Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg | |
BRPI0517976A (pt) | métodos de tratamento | |
DK1169059T3 (da) | Docetaxel i kombination med rhuMAb HER2 til behandling af cancere | |
Rampino et al. | Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial | |
BRPI0413974A (pt) | combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação | |
HK1071310A1 (en) | Combination therapy for the treatment of cancer | |
Adışen et al. | Ultraviolet A1 phototherapy in the treatment of early mycosis fungoides | |
Oing et al. | Palliative treatment of germ cell cancer | |
MX2021002349A (es) | Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario. | |
MX2021009051A (es) | Tratamiento de lesiones cutaneas y prurito en pacientes con prurigo nodular. | |
WO2005113720A3 (en) | A strategy for designing patient-specific anti-cancer drugs | |
De Santis et al. | Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery: a phase I trial | |
Magno et al. | Double-blind randomized study of lonidamine and radiotherapy in head and neck cancer | |
Marcenaro et al. | Ablative or palliative stereotactic body radiotherapy with helical tomotherapy for primary or metastatic lung tumor | |
EA201270298A1 (ru) | Способ лечения злокачественной опухоли | |
WO2006124573A3 (en) | Treatment of cancer with 2-deoxyglucose | |
Stellamans et al. | Does sucralfate reduce early side effects of pelvic radiation? A double-blind randomized trial | |
Wrenn et al. | A Phase I Study using low-dose fractionated whole abdominal radiotherapy as a chemopotentiator to full-dose cisplatin for optimally debulked stage III/IV carcinoma of the endometrium | |
MX2012005497A (es) | Tivozanib y temsirolimus en combinacion. | |
ATE537838T1 (de) | Kombinationstherapie mit kloretazin(tm) | |
TW200501958A (en) | A therapeutic agent for treating a behavioral disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |